New EGFR-Targeting ADC Shows Promise in Heavily Pretreated Lung Cancer Patients
SYS6010, a novel antibody-drug conjugate, achieves up to 45.7% response rates in EGFR-mutant NSCLC after prior TKI failure.
Summary
SYS6010 is a new antibody-drug conjugate (ADC) that targets EGFR, a protein commonly overactive in lung cancer cells. In a phase 1 trial of 236 patients with advanced non-small cell lung cancer (NSCLC) who had already received standard treatments, SYS6010 demonstrated meaningful tumor-shrinking activity across multiple patient subgroups. In EGFR-mutant patients who had progressed after both TKI therapy and platinum chemotherapy — historically one of the hardest groups to treat — 34.7% responded to treatment. Among those who had received only TKIs previously, response rates climbed to 45.7%. Even patients with EGFR wild-type tumors showed responses. Median overall survival reached 19.4 months in the most pretreated group. Side effects were significant, with over half experiencing grade 3 or higher toxicities, particularly blood count reductions, but the profile was considered manageable. These results position SYS6010 as a potentially important new option for a cancer type that remains a leading cause of cancer mortality worldwide.
Detailed Summary
Lung cancer remains the world's deadliest cancer, and despite major advances with EGFR-targeted therapies, nearly all patients eventually develop resistance. Once patients progress through EGFR tyrosine kinase inhibitors (TKIs) and platinum-based chemotherapy, treatment options narrow dramatically. SYS6010, an antibody-drug conjugate (ADC) developed by CSPC Pharmaceutical Group, aims to address this unmet need by delivering cytotoxic payload directly to EGFR-expressing tumor cells.
This phase 1 trial enrolled 236 patients with advanced NSCLC across multiple Chinese centers. Researchers tested escalating doses of SYS6010 to identify the optimal therapeutic range. One dose-limiting toxicity was observed at 6.4 mg/kg, leading investigators to select 4.2, 4.5, and 4.8 mg/kg for expansion cohorts. The trial design allowed evaluation across distinct patient subgroups defined by EGFR mutation status and prior treatment history.
The efficacy results were encouraging across the board. The objective response rate (ORR) reached 45.7% in EGFR-mutant patients previously treated with TKIs alone, and 34.7% in those who had additionally received platinum chemotherapy — a heavily pretreated population. EGFR wild-type patients also responded, with ORRs of 20.0% in squamous and 35.7% in non-squamous subtypes. In the most comprehensively pretreated group, median progression-free survival was 7.6 months and median overall survival was 19.4 months.
On the safety side, nearly all patients (99.6%) experienced treatment-related adverse events, with 57.2% experiencing grade 3 or higher events. The most common severe toxicities were hematological: neutropenia (30.9%), leukopenia (25.0%), and thrombocytopenia (17.4%). These are consistent with other ADC platforms and are generally manageable with supportive care and dose modifications.
SYS6010 joins a growing class of EGFR-targeting ADCs reshaping the treatment landscape for NSCLC. Its broad activity across mutation statuses is particularly noteworthy. Key caveats include the single-arm phase 1 design, the predominantly Chinese patient population, and that this summary is based on the abstract alone.
Key Findings
- 45.7% objective response rate in EGFR-mutant NSCLC after prior TKI therapy, with no platinum chemotherapy.
- 34.7% response rate in the hardest-to-treat group: EGFR-mutant patients post-TKI and platinum chemotherapy.
- Median overall survival of 19.4 months achieved in heavily pretreated EGFR-mutant patients.
- Responses observed even in EGFR wild-type tumors (20–35.7%), expanding potential eligible population.
- Grade ≥3 adverse events in 57.2% of patients, driven mainly by manageable hematological toxicities.
Methodology
This was a phase 1, dose-escalation and expansion trial (ChiCTR2300072141) enrolling 236 patients with advanced NSCLC across multiple Chinese oncology centers. Patients were stratified by EGFR mutation status and prior treatment history. Doses escalated from lower levels up to 6.4 mg/kg, with 4.2, 4.5, and 4.8 mg/kg selected for cohort expansion after one dose-limiting toxicity at the highest level.
Study Limitations
This summary is based on the abstract only, as the full paper is not open access. The single-arm, non-randomized phase 1 design limits causal conclusions and precludes comparison to standard-of-care benchmarks. The trial was conducted exclusively in Chinese centers, which may limit generalizability to other ethnic and genetic populations.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: